# A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Source: https://onco.cc/trials/nct02662634/  
OnCo record `nct02662634` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rocapuldencel-T run by GU Research Network, LLC, withdrawn before enrolling.

## Summary

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer is a phase 2 interventional study registered as NCT02662634 by GU Research Network, LLC, started 2016-03. Conditions recorded: Non-small Cell Lung Cancer (NSCLC). Interventions recorded: AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol and Radiation Therapy.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02662634
- Phase: 2
- Setting: A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
- Sponsor: GU Research Network, LLC

## Sources

- ClinicalTrials.gov NCT02662634: https://clinicaltrials.gov/study/NCT02662634

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Rocapuldencel-T](https://onco.cc/drugs/rocapuldencel-t/)
- companies: [Argos Therapeutics](https://onco.cc/companies/argos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct02662634.json